AVA6000 Elicits Clinically Meaningful Tumor Shrinkage in Salivary Gland Cancer
Preliminary data show that AVA6000 led to robust and clinically meaningful tumor shrinkage in patients with salivary gland cancer.
Related Articles
Trump calls for U.S. to withdraw from World Health Organization
The move to exit the WHO is historic and controversial. The U.S. has long been the most generous provider of humanitarian assistance.
Dr Nathanson on BRCA1/2 Reversion Mutations in Response to Therapy in Breast Cancer
Katherine L. Nathanson, MD, discusses the identification of reversion mutations in BRCA1/2 in response to therapy among patients with breast cancer.
President Trump repeals Biden’s AI executive order | TechCrunch
President Trump has revoked a 2023 executive order signed by former President Biden that sought to reduce the potential risks AI poses.
Defective homologous recombination and genomic instability predict increased responsiveness to carbon ion radiotherapy in pancreatic cancer
npj Precision Oncology – Defective homologous recombination and genomic instability predict increased responsiveness to carbon ion radiotherapy in pancreatic cancer
Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial
Pembrolizumab in combination with bevacizumab was more efficacious than pembrolizumab monotherapy, with manageable toxicities in platinum-resistant nasopharyngeal carcinoma. If validated in a phase 3 trial,…
Pembrolizumab Plus SBRT Fails to Improve Survival in Unresected Stage I/II NSCLC
The addition of pembrolizumab to radiation did not improve survival in unresected, stage I or II non–small cell lung cancer.
Out-of-area mental health placements: we must increase resources for severe mental illness and capacity for inpatient care
The Health Services Safety Investigations Body (HSSIB) report1 on out-of-area mental health inpatient placements provides a welcome spotlight on the problem.2 Psychiatrists have, however, repeatedly…
When to Stay or Leave Your Physician Job – FREE Webinar
At the free, LIVE class, you’ll get everything you need to make your decision & upgrade your job in 2025, regardless if you stay or…
Bispecific antibodies: advancing precision oncology – PubMed
Bispecific antibodies (bsAbs) are engineered molecules designed to target two different epitopes or antigens. The mechanism of action is determined by the bsAb molecular targets…
5-Year Follow-Up Data for Tremelimumab Plus Durvalumab in Unresectable HCC
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.